Dexamethasone is NOT Recommended for Acute Stroke
Dexamethasone should not be used in patients with acute intracerebral hemorrhage (ICH) or acute ischemic stroke outside of clinical trials. The European Stroke Organisation explicitly recommends against dexamethasone use in acute ICH 1, and there is no guideline support for its use in acute ischemic stroke.
Key Guideline Recommendations
The 2014 ESO guidelines provide a moderate quality of evidence with weak strength recommendation AGAINST dexamethasone in acute ICH patients 1. This represents the highest-quality guideline evidence available on this topic and should guide clinical practice.
The Evidence Landscape
Why Dexamethasone Fails in Stroke
The rationale against corticosteroids in acute stroke is multifactorial:
Ischemic stroke: Historical trials from the 1980s showed no benefit. A 1986 randomized controlled trial of high-dose dexamethasone (480 mg over 12 days) in 113 patients with acute cerebral infarction demonstrated no significant difference in mortality or quality of survival compared to placebo 2. The authors concluded that any marginal therapeutic effect would expose patients to serious steroid complications and potentially convert patients who would have died into neurovegetative survivors.
Hemorrhagic stroke: A 2001 double-blind RCT using 100 mg dexamethasone stat followed by 16 mg every 6 hours for 48 hours showed no mortality benefit at 1 month (80% mortality in dexamethasone group vs 85% in placebo) 3.
Contradictory Observational Data (Lower Quality)
One retrospective study from Crete suggested benefit 4, and a 2025 propensity-matched analysis from MIMIC-IV database suggested low-dose dexamethasone might reduce short-term mortality in ICH 5. However, these observational studies cannot override guideline recommendations based on randomized trials. The Crete study represents a single-center experience with potential unmeasured confounders, and the MIMIC-IV analysis showed concerning findings: only low doses appeared beneficial, higher doses increased mortality risk, and benefits were limited to short-term outcomes with no long-term survival advantage 5.
The Only Exception: Cerebral Edema from Brain Tumors
The FDA label for dexamethasone does indicate use for cerebral edema associated with brain tumors (10 mg IV initially, then 4 mg every 6 hours IM until symptoms subside) 6. This is distinctly different from stroke-related edema and should not be extrapolated to acute stroke management.
Common Pitfalls to Avoid
Do not confuse tumor-related edema with stroke-related edema: The pathophysiology differs fundamentally, and dexamethasone's mechanism of action (reducing vasogenic edema around tumors) does not translate to cytotoxic or ischemic edema in stroke.
Do not be swayed by single-center observational data: The Crete study, while intriguing, represents hypothesis-generating data that requires validation in prospective randomized trials before changing practice.
Recognize steroid complications: High-dose corticosteroids carry significant risks including hyperglycemia (particularly problematic in stroke), infection, GI bleeding, and impaired wound healing—all of which can worsen stroke outcomes.
What to Do Instead
For elevated intracranial pressure in stroke patients, the ESO guidelines note insufficient evidence for specific ICP-lowering measures but do not recommend steroids 1. Focus on: